The controlling shareholder of Intel Group (000411.SZ) plans to change to Zhejiang Pharmaceutical Group

Zhitong Finance App News, Intel Group (000411.SZ) announced that on October 15, 2024, the company received a notice from Zhejiang Pharmaceutical and Health Industry Group Co., Ltd. (“Zhejiang Pharmaceutical Group”, “acquirer” for short). According to the unified deployment of state-owned assets supervision, Zhejiang Pharmaceutical Group will become the main enterprise in the pharmaceutical industry chain in Zhejiang Province and the main investment platform for the pharmaceutical industry in Zhejiang Province to invest and cultivate outstanding life and health enterprises with the most strategic value to promote their services and improve human health.

The company's shareholder Zhejiang Huachen Investment and Development Co., Ltd. (“Huachen Investment”) transferred 122 million shares of the company to Zhejiang Pharmaceutical Group, the controlling shareholder of Huachen Investment; at the same time, Zhejiang International Trade Group Co., Ltd. (“Zhejiang Guomao”), the controlling shareholder of the company, delegated voting rights corresponding to 151 million shares of the company to Zhejiang Pharmaceutical Group, a wholly-owned subsidiary of Zhejiang International Trade. After this change in equity, Zhejiang Pharmaceutical Group can actually control the voting rights corresponding to the 322 million shares of Intel Group (accounting for 61.67% of Intel Group's total share capital as of September 30, 2024). After this change in equity, the controlling shareholder of the company was changed from Zhejiang Guomao to Zhejiang Pharmaceutical Group. The actual controller of the company has not changed; it is still the State-owned Assets Supervision and Administration Commission of the Zhejiang Provincial People's Government (“Zhejiang Provincial State-owned Assets Administration Commission” for short).